JUN and cancer: To further supplement the bioinformatics analyses, we identified HLA class I-presented peptides from common proto-oncogenes, such as KRAS, EGFR, MYC, JUN, and tumor suppressors, such as TP53, RB1, and BRCA2. We identified 17 common cancer driver gene–derived wildtype peptides presented by HLA class I in lung adenocarcinoma cell lines/tumor and two peptides in primary tumor–derived melanoma cells; six of which are novel peptides not previously reported.